Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CanSino to Add Shanghai Star Board IPO to Hong Kong Listing

publication date: Oct 14, 2019

CanSino Biologics, a Tianjin vaccine company, filed to IPO on the Shanghai Star Board, six months after it completed a $161 million initial offering in Hong Kong. In the first day of trading following the Hong Kong IPO, CanSino rose 58%, and it remains 72% above the IPO price six months later. The company said it would issue 24.8 million shares in the Shanghai offering, but it has not set its pricing goals yet. CanSino has an approved Ebola vaccine and six vaccine candidates in clinical trials or CTA stage, along with 6 pre-clinical vaccine candidates. More details....

Stock Symbol: (HK: 6185)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here